<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734210</url>
  </required_header>
  <id_info>
    <org_study_id>C-200-001</org_study_id>
    <nct_id>NCT04734210</nct_id>
  </id_info>
  <brief_title>A Research Study to See How Well an Eye Drop, SURF-200 (0.02% and 0.04% Betamethasone Sodium Phosphate), Works, What Side Effects There Are, and to Compare it With Vehicle (Placebo) in Subjects Diagnosed With Dry Eye Disease and Experiencing An Episodic Flare-Up</brief_title>
  <official_title>A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Surface Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Surface Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye&#xD;
      disease. SURF-200 is an investigational drug (which means the study drug is currently being&#xD;
      tested) in the form of a sterile eye drop.&#xD;
&#xD;
      The purpose of this research study is to see how well SURF-200 works and what side effects&#xD;
      there are, and to compare it with vehicle (placebo). The study will involve about 120 study&#xD;
      participants at multiple research sites in the United States.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UNC DEMS Score</measure>
    <time_frame>Day 8</time_frame>
    <description>A minimum reduction of 1 unit in patient-reported dry eye disease symptoms and reduction of impact of symptoms with SURF-200 as compared to vehicle (as measured by the University of North Carolina [UNC] Dry Eye Management Scale [DEMS]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UNC DEMS Score</measure>
    <time_frame>Day 15</time_frame>
    <description>A minimum reduction of 1 unit in patient-reported dry eye disease symptoms and reduction of impact of symptoms with SURF-200 as compared to vehicle (as measured by the University of North Carolina [UNC] Dry Eye Management Scale [DEMS]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Hyperemia Assessment</measure>
    <time_frame>Day 8</time_frame>
    <description>A minimum reduction of 0.5 points in conjunctival hyperemia with SURF-200 as compared to vehicle using the Conjunctival Hyperemia Assessment 4 point scale (0-3) in the study eye.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>SURF-200 (0.02% betamethasone sodium phosphate in vehicle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop twice daily (BID) in the study eye for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SURF-200 (0.04% betamethasone sodium phosphate in vehicle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop BID in the study eye for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop BID in the study eye for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.02% Betamethasone Sodium Phosphate</intervention_name>
    <description>topical corticosteroid solution</description>
    <arm_group_label>SURF-200 (0.02% betamethasone sodium phosphate in vehicle)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.04% Betamethasone Sodium Phosphate</intervention_name>
    <description>topical corticosteroid solution</description>
    <arm_group_label>SURF-200 (0.04% betamethasone sodium phosphate in vehicle)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>topical vehicle solution</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects 18 years of age and older who have a diagnosis of dry eye disease and&#xD;
             experiencing an episodic flare up. Criteria for the diagnosis must include the&#xD;
             following:&#xD;
&#xD;
               1. UNC DEMS score of greater than or equal to 5 but less than or equal to 9&#xD;
&#xD;
               2. Conjunctival hyperemia score of greater than or equal to 2 in the study eye when&#xD;
                  using the conjunctival hyperemia reference photos&#xD;
&#xD;
               3. Schirmer's Tear Test score (with anesthesia) greater than 1 mm but less than or&#xD;
                  equal to12 mm in the study eye&#xD;
&#xD;
          2. Subjects must be able to understand and sign the Informed Consent Form (ICF).&#xD;
&#xD;
          3. Female subjects of childbearing potential must agree to and submit a negative urine&#xD;
             pregnancy test before any study-specific procedures are performed. The subjects must&#xD;
             be using and continue to use a suitable method of contraception for the duration of&#xD;
             the study: spermicide with barrier, oral contraceptive, transdermal contraceptive,&#xD;
             injectable or implantable contraceptive, intrauterine device (IUD), abstinence or&#xD;
             surgical sterilization of a partner. If a subject is not of childbearing potential&#xD;
             (e.g., has been postmenopausal for at least 12 months or is premenarchal, or has&#xD;
             undergone a hysterectomy, bilateral oophorectomy or a bilateral tubal ligation), a&#xD;
             urine pregnancy test and use of a suitable method of contraception for the duration of&#xD;
             the study will not be required.&#xD;
&#xD;
          4. Subjects must have a best-corrected visual acuity (BCVA) of at least +1.0 log of the&#xD;
             minimum angle of resolution (logMAR) (Snellen equivalent of 20/200) in the non-study&#xD;
             eye (fellow eye).&#xD;
&#xD;
          5. Subjects must have an intraocular pressure (IOP) of &gt;8 mmHg and â‰¤22 mmHg in the study&#xD;
             eye.&#xD;
&#xD;
          6. Subjects who are on Restasis, Xiidra or other cyclosporine ophthalmic eye drops must&#xD;
             be on a stable dose for at least 4 months prior to Screening Visit 1 (Day -14 to Day&#xD;
             0) and remain compliant with the use of these medications throughout the duration of&#xD;
             this study.&#xD;
&#xD;
          7. Subjects who are on artificial tears, oral antihistamines, beta blockers and diuretics&#xD;
             must be on a stable dose for at least 1 month prior to Screening Visit 1 (Day -14 to&#xD;
             Day 0) and remain compliant with the use of these medications throughout the duration&#xD;
             of this study.&#xD;
&#xD;
          8. Subjects must be willing and able to attend all study visits and follow all&#xD;
             instructions.&#xD;
&#xD;
          9. Subjects must be able to self-instill the study drug (if unable, a caregiver must be&#xD;
             available to instill all doses of the study drug).&#xD;
&#xD;
         10. Have a history of use or desire to use an eye drop for dry eye symptoms for longer&#xD;
             than the past 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or nursing or planning to become pregnant during the study.&#xD;
             Females of childbearing potential (not surgically sterilized or postmenopausal) may&#xD;
             not participate in the study if they do not agree to use adequate birth control&#xD;
             methods for the duration of the study.&#xD;
&#xD;
          2. Use of contact lenses in either eye during the study. Contact lens wear must have been&#xD;
             discontinued at least 2 weeks prior to Baseline/Randomization Visit 2 (Day 1).&#xD;
&#xD;
          3. Use of corticosteroids or nonsteroidal anti-inflammatory agents (NSAID) (except oral&#xD;
             doses of aspirin at 81 mg/day or lower) within 2 weeks of the initiation of study drug&#xD;
             at Baseline/Randomization Visit 2 (Day 1) and for the remainder of the study.&#xD;
&#xD;
          4. Inhaled, ingested, sublingual, transdermal or topical products containing marijuana,&#xD;
             tetrahydrocannabinol (THC) or cannabidiol (CBD) within 7 days of the first dose of&#xD;
             study drug at Baseline/Randomization Visit 2 (Day 1) and for the remainder of the&#xD;
             study.&#xD;
&#xD;
          5. Presence or history of treatment with systemic immunosuppressive or chemotherapeutic&#xD;
             agents.&#xD;
&#xD;
          6. History of high IOP response to steroids.&#xD;
&#xD;
          7. Participated in an ophthalmic investigational product clinical trial within 30 days of&#xD;
             Screening Visit 1 (Day -14 to Day 0).&#xD;
&#xD;
          8. Active collagen vascular disorder or autoimmune disease.&#xD;
&#xD;
          9. A condition or a situation, which in the investigator's opinion may put the subject at&#xD;
             increased risk, confound study data, or interfere significantly with the subject's&#xD;
             study participation.&#xD;
&#xD;
         10. Known hypersensitivity to any component of the study drug or procedural medications.&#xD;
&#xD;
         11. Known hypersensitivity to steroids.&#xD;
&#xD;
         12. Any active corneal epithelial/stromal pathology noted in the study eye at Screening&#xD;
             Visit 1 (Day -14 to Day 0).&#xD;
&#xD;
         13. Any history of corneal surgery in the study eye (including corneal crosslinking,&#xD;
             radial keratotomy, corneal transplant, or LASIK).&#xD;
&#xD;
         14. Any ocular surgery in the study eye within the past year.&#xD;
&#xD;
         15. Subject has punctal occlusion with any modality or a change in punctal plug status in&#xD;
             either eye within the 3 months prior to Screening Visit 1 (Day -14 to Day 0).&#xD;
&#xD;
         16. Subject has a history of glaucoma.&#xD;
&#xD;
         17. Subject has a history of herpes simplex infection in either eye.&#xD;
&#xD;
         18. Subject has active corneal, conjunctival or canalicular pathology (including ocular&#xD;
             infection [bacterial, viral or fungal]) in either eye. Specifically, active viral&#xD;
             diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis&#xD;
             (dendritic keratitis), vaccinia, and varicella, and mycobacterial infection of either&#xD;
             eye and fungal diseases of the ocular structures (such as fungal keratitis).&#xD;
&#xD;
         19. Subject has thinning of the cornea or sclera in the study eye.&#xD;
&#xD;
         20. Subject has active anterior blepharitis in the study eye.&#xD;
&#xD;
         21. Subject has a history of uveitis in the study eye.&#xD;
&#xD;
         22. Subject is suffering from alcohol and/or drug abuse.&#xD;
&#xD;
         23. Subject has tested positive for the COVID-19 virus within 30 days prior to Screening&#xD;
             Visit 1 (Day -14 to Day 0).&#xD;
&#xD;
         24. Subject has previously received treatment in this study protocol.&#xD;
&#xD;
         25. Subject is taking a medication, that in the opinion of the investigator, might&#xD;
             interfere with the study parameters.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamran Hosseini, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Surface Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sponsor Company's Vice President of Clinical Operations</last_name>
    <phone>(925) 494-3660</phone>
    <phone_ext>18</phone_ext>
    <email>cbaenziger@surfaceophthalmics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sponsor Company's Director of Clinical Operations</last_name>
    <phone>(925) 494-3660</phone>
    <phone_ext>7</phone_ext>
    <email>kmorrison@surfaceophthalmics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Trinity Research Group</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Ivey</last_name>
      <phone>334-993-2111</phone>
      <email>emilyp.trinity@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sebastian Heersink</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group, Inc.</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Rodriguez</last_name>
      <phone>818-365-0606</phone>
      <email>rrodriguez@northvalleyeye.net</email>
    </contact>
    <investigator>
      <last_name>Robert Smyth-Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LoBue Laser and Eye Medical Center</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikayla Gates</last_name>
      <phone>951-696-1135</phone>
      <email>mikaylag@lobueeyecenters.com</email>
    </contact>
    <contact_backup>
      <last_name>Erin Schaefer</last_name>
      <phone>951-696-1135</phone>
      <email>cataracts@lobueeyecenters.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ryan Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Visionary Eye Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Ceballos</last_name>
      <phone>949-528-3608</phone>
      <email>a.ceballos@visionsaryeyeinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Ehsan Sadri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Chavez</last_name>
      <phone>707-769-2240</phone>
      <email>echavez@northbayeye.com</email>
    </contact>
    <investigator>
      <last_name>Jason Bacharach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martel Eye Medical Group</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Karpach</last_name>
      <phone>916-631-7860</phone>
      <email>nataliya.marteleye@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Martel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vision Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Agbo</last_name>
      <phone>719-559-2020</phone>
      <email>helene@vicolorado.com</email>
    </contact>
    <investigator>
      <last_name>Erik Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Center of Northern Colorado</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Moon</last_name>
      <phone>970-419-2696</phone>
      <email>courtneym@eyecenternoco.com</email>
    </contact>
    <investigator>
      <last_name>Karl Olsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Eye Consultants, PC</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Smit</last_name>
      <phone>203-791-2020</phone>
      <phone_ext>256</phone_ext>
      <email>clinicaleye@danburyeye.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Associates of Manatee</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khrystina Cozby</last_name>
      <phone>941-220-5987</phone>
      <email>kcozby@theeyeassociates.com</email>
    </contact>
    <contact_backup>
      <last_name>Carole Kringel</last_name>
      <phone>941-220-5987</phone>
      <email>ckringel@theeyeassociates.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cathleen McCabe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blue Ocean Clinical Research (The Macula Center)</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Munoz</last_name>
      <phone>727-789-8770</phone>
      <email>smunoz@vip-us.net</email>
    </contact>
    <investigator>
      <last_name>Dana Deupree</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Associates of Fort Myers</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carissa Smith</last_name>
      <phone>239-939-0413</phone>
      <phone_ext>324</phone_ext>
      <email>cesmith@easwfl.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Center of North Florida PA</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Menck</last_name>
      <phone>850-784-3937</phone>
      <email>eyenerdgyrl1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bret Fisher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates, LLC</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Schuhr</last_name>
      <phone>770-777-1928</phone>
      <email>John@coastalresearchassociates.com</email>
    </contact>
    <investigator>
      <last_name>Susanne Hewitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Hogeback</last_name>
      <phone>859-331-9000</phone>
      <email>khogeback@cvphealth.com</email>
    </contact>
    <investigator>
      <last_name>Edward Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentucky Eye Institute</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Douglas</last_name>
      <phone>859-278-9393</phone>
      <email>christy.douglas@kyeye.com</email>
    </contact>
    <investigator>
      <last_name>Paul Karpecki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Vision Institute</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Trevino</last_name>
      <phone>952-835-1235</phone>
      <email>jessica.trevino@chuvision.com</email>
    </contact>
    <contact_backup>
      <last_name>Hayley Jacobs</last_name>
      <phone>952-835-1235</phone>
      <email>Hayley.jacobs@chuvision.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yun-sen (Ralph) Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Hefter</last_name>
      <phone>816-531-9100</phone>
      <email>mh@taubereye.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Tauber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Consultants Ltd.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Williams</last_name>
      <phone>314-646-4413</phone>
      <email>swilliams@ocstl.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Gira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alterman, Modi &amp; Wolter</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Piza</last_name>
      <phone>845-454-1025</phone>
      <phone_ext>204</phone_ext>
      <email>sortiz523@aol.com</email>
    </contact>
    <investigator>
      <last_name>Satish Modi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates, PC</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Hindman</last_name>
      <phone>724-772-3000</phone>
      <email>nhindman@scottandchristie.com</email>
    </contact>
    <contact_backup>
      <last_name>Emily Nolte</last_name>
      <email>enolte@scottandchristie.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Zimmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bucci Laser Vision</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanne Michalek</last_name>
      <phone>570-825-5949</phone>
      <email>breanne@buccivision.com</email>
    </contact>
    <investigator>
      <last_name>Frank Bucci Jr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, PA</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ashe</last_name>
      <phone>901-760-4620</phone>
      <email>dashe.tec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Laser Vision &amp; Surgical Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>R and R Eye Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Hazen</last_name>
      <phone>210-424-2584</phone>
      <email>maggie@eye-assoc.com</email>
    </contact>
    <contact_backup>
      <last_name>Griselda Rodriguez</last_name>
      <phone>210-424-2584</phone>
      <email>gracie@eye-assoc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Brunin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

